BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, Wettstein AR, Field A. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17:135-139. [PMID: 11966942 DOI: 10.1046/j.1440-1746.2002.02564.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(2): 450-453 [DOI: 10.11569/wcjd.v12.i2.450] [Reference Citation Analysis]
2 Ma J, Ning YN, Xu M, Hou Y, Wang N, Hou XY, Yu YY, Li H, He WD, Shao LL. Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia. Blood. 2013;122:2074-2082. [PMID: 23926306 DOI: 10.1182/blood-2013-03-491555] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
3 Liu M, Lin X, Wang L, He Y, Chen M, Mao R. Thalidomide-induced sinus bradycardia in Crohn's disease: case report and literature review. J Int Med Res 2019;47:2228-33. [PMID: 30832535 DOI: 10.1177/0300060519833293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Vale ML, Cunha FQ, Brito GA, Benevides VM, Ferreira SH, Poole S, Ribeiro RA. Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation. European Journal of Pharmacology 2006;536:309-17. [DOI: 10.1016/j.ejphar.2006.02.051] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
5 Gerich ME, Yoon JL, Targan SR, Ippoliti AF, Vasiliauskas EA. Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther 2015;41:429-37. [PMID: 25511905 DOI: 10.1111/apt.13057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
6 Fernandes C, Allocca M, Danese S, Fiorino G. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 2015;7:175-90. [PMID: 25713992 DOI: 10.2217/imt.14.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
7 Metz DC, Vakil N, Keeffe EB, Lichtenstein GR. Advances in Gastrointestinal Pharmacotherapy. Clinical Gastroenterology and Hepatology 2005;3:1167-79. [DOI: 10.1016/s1542-3565(05)00895-5] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
8 Srinivasan R, Akobeng AK. Thalidomide and thalidomide analogues for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;CD007350. [PMID: 19370684 DOI: 10.1002/14651858.cd007350.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
9 Barkin JA, Schonfeld WB, Deshpande AR. Successful Use of Thalidomide for Refractory Esophageal Crohn's Disease. American Journal of Gastroenterology 2013;108:855-7. [DOI: 10.1038/ajg.2013.49] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
10 Leite MR, Santos SS, Lyra AC, Mota J, Santana GO. Thalidomide induces mucosal healing in Crohn's disease: Case report. World J Gastroenterol 2011; 17(45): 5028-5031 [PMID: 22174554 DOI: 10.3748/wjg.v17.i45.5028] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
11 Lopalco G, Rigante D, Venerito V, Fabiani C, Franceschini R, Barone M, Lapadula G, Galeazzi M, Frediani B, Iannone F, Cantarini L. Update on the Medical Management of Gastrointestinal Behçet's Disease. Mediators Inflamm 2017;2017:1460491. [PMID: 28210071 DOI: 10.1155/2017/1460491] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
12 Zhu Z, Li M, Shu X, Bai A, Long S, Liu D, Lu N, Zhu X, Liao W. Thalidomide is a therapeutic agent that is effective in inducing and maintaining endoscopic remission in adult CD patients. Clinics and Research in Hepatology and Gastroenterology 2017;41:210-6. [DOI: 10.1016/j.clinre.2016.09.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
13 Iskandar H, Greer JB, Krasinskas AM, Tinsley AT, Koltun WA, Siegel CA, Levy LC, Herfarth HH, Farraye FA, Binion DG, Rosh JR, Keljo DJ, Isaacs KL, Regueiro MD. IBD LIVE Series-Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa. Inflamm Bowel Dis 2017;23:1667-77. [PMID: 28906288 DOI: 10.1097/MIB.0000000000001266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chidlow JH, Langston W, Greer JJ, Ostanin D, Abdelbaqi M, Houghton J, Senthilkumar A, Shukla D, Mazar AP, Grisham MB. Differential angiogenic regulation of experimental colitis. Am J Pathol. 2006;169:2014-2030. [PMID: 17148665 DOI: 10.2353/ajpath.2006.051021] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 6.6] [Reference Citation Analysis]
15 Akobeng AK, Stokkers PC. Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;CD007351. [PMID: 19370685 DOI: 10.1002/14651858.cd007351.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
16 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
17 Khan MA, Carducci MA, Partin AW. The Evolving Role of Docetaxel in the Management of Androgen Independent Prostate Cancer. Journal of Urology 2003;170:1709-16. [DOI: 10.1097/01.ju.0000088787.95124.4b] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
18 Hegarty A, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn’s disease and orofacial granulomatosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:576-585. [PMID: 12738949 DOI: 10.1067/moe.2002.113] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
19 Levy AN, Ali N, Andrici J, Hamilton MJ. It's What's Up Front That Counts-Part Two: Esophageal Crohn's Disease Complicated by Recurrent Upper Gastrointestinal Bleeding. Dig Dis Sci 2019;64:3446-50. [PMID: 31677072 DOI: 10.1007/s10620-019-05922-x] [Reference Citation Analysis]
20 Chidlow JH Jr, Glawe JD, Pattillo CB, Pardue S, Zhang S, Kevil CG. VEGF₁₆₄ isoform specific regulation of T-cell-dependent experimental colitis in mice. Inflamm Bowel Dis 2011;17:1501-12. [PMID: 21674706 DOI: 10.1002/ibd.21525] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
21 Koopmans GC, Deumens R, Buss A, Geoghegan L, Myint AM, Honig WH, Kern N, Joosten EA, Noth J, Brook GA. Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury. Exp Neurol 2009;216:490-8. [PMID: 19320007 DOI: 10.1016/j.expneurol.2009.01.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
22 Cheon JH, Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease. Curr Opin Rheumatol 2015;27:24-31. [PMID: 25405821 DOI: 10.1097/BOR.0000000000000125] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
23 Paredes JM, Barrachina MM, Román J, Moreno-Osset E. [Joint disease in inflammatory bowel disease]. Gastroenterol Hepatol 2005;28:240-9. [PMID: 15811268 DOI: 10.1157/13073095] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Diamanti A, Capriati T, Papadatou B, Knafelz D, Bracci F, Corsetti T, Elia D, Torre G. The clinical implications of thalidomide in inflammatory bowel diseases. Expert Rev Clin Immunol. 2015;11:699-708. [PMID: 25865355 DOI: 10.1586/1744666x.2015.1027687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
25 McConnell EL, Liu F, Basit AW. Colonic treatments and targets: issues and opportunities. J Drug Target 2009;17:335-63. [PMID: 19555265 DOI: 10.1080/10611860902839502] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.5] [Reference Citation Analysis]
26 Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R. Histologic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev 2017;7:CD012351. [PMID: 28731502 DOI: 10.1002/14651858.CD012351.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lazzerini M, Villanacci V, Pellegrin MC, Martelossi S, Magazzù G, Pellegrino S, Lucanto MC, Barabino A, Calvi A, Arrigo S, Lionetti P, Fontana M, Zuin G, Maggiore G, Bramuzzo M, Maschio M, Salemme M, Manenti S, Lorenzi L, Decorti G, Montico M, Ventura A. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. Clin Gastroenterol Hepatol 2017;15:1382-1389.e1. [PMID: 28286192 DOI: 10.1016/j.cgh.2017.02.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
28 De Keersmaecker B, Allard SD, Lacor P, Schots R, Thielemans K, Aerts JL. Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs. J Virol 2012;86:9351-60. [PMID: 22718823 DOI: 10.1128/JVI.00472-12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
29 Nasca MR, Micali G, Cheigh NH, West LE, West DP. Dermatologic and Nondermatologic Uses of Thalidomide. Ann Pharmacother 2003;37:1307-20. [DOI: 10.1345/aph.19255] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
30 Guo XG, Sun AH, Li CN, Zhang HB, Zhou XM, Xu CT, Pan BR. Effects of parenteral hyperalimentation on serum motilin, peptide YY, IgG and glycoproteins in severe ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2003; 11(2): 224-228 [DOI: 10.11569/wcjd.v11.i2.224] [Reference Citation Analysis]
31 Caprilli R, Angelucci E, Cocco A, Viscido A, Zippi M. Efficacy of conventional immunosuppressive drugs in IBD. Digestive and Liver Disease 2004;36:766-80. [DOI: 10.1016/j.dld.2004.06.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
32 Fritze D, Zhang W, Li JY, Chai B, Mulholland MW. TNFα causes thrombin-dependent vagal neuron apoptosis in inflammatory bowel disease. J Gastrointest Surg 2014;18:1632-41. [PMID: 24961441 DOI: 10.1007/s11605-014-2573-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
33 Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363:1802-1811. [PMID: 15172781 DOI: 10.1016/s0140-6736(04)16308-3] [Cited by in Crossref: 364] [Cited by in F6Publishing: 105] [Article Influence: 20.2] [Reference Citation Analysis]
34 Isaacs KL. Crohn's disease of the esophagus. Curr Treat Options Gastroenterol 2007;10:61-70. [PMID: 17298766 DOI: 10.1007/s11938-007-0058-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
35 Cohen RD. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep 2002;4:497-505. [DOI: 10.1007/s11894-002-0026-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
36 Kim DH, Cheon JH. Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis? Yonsei Med J 2016;57:22-32. [PMID: 26632379 DOI: 10.3349/ymj.2016.57.1.22] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 7.2] [Reference Citation Analysis]
37 Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, Ventura A. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther. 2007;25:419-427. [PMID: 17269997 DOI: 10.1111/j.1365-2036.2006.03211.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
38 Gordon JN, Prothero JD, Thornton CA, Pickard KM, Di Sabatino A, Goggin PM, Pender SL, Macdonald TT. CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease. J Crohns Colitis 2009;3:175-82. [PMID: 21172267 DOI: 10.1016/j.crohns.2009.03.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
39 Faubion WA, Bousvaros A. Medical Therapy for Refractory Pediatric Crohn’s Disease. Clinical Gastroenterology and Hepatology 2006;4:1199-213. [DOI: 10.1016/j.cgh.2006.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
40 Korzenik JR. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab. Gastroenterol Clin North Am. 2004;33:285-301, ix. [PMID: 15177539 DOI: 10.1016/j.gtc.2004.02.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
41 Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007;47:930-941. [PMID: 17567930 DOI: 10.1177/0091270007301623] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 5.6] [Reference Citation Analysis]
42 Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis. Aliment Pharmacol Ther Symp Series 2006;2:147-52. [DOI: 10.1111/j.1746-6342.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Bramuzzo M, Ventura A, Martelossi S, Lazzerini M. Thalidomide for inflammatory bowel disease: Systematic review. Medicine (Baltimore) 2016;95:e4239. [PMID: 27472695 DOI: 10.1097/MD.0000000000004239] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 5.6] [Reference Citation Analysis]
44 Cheon JH, Çelik AF, Kim WH. Behçet’s Disease: Gastrointestinal Involvement. In: Yazıcı Y, Yazıcı H, editors. Behçet’s Syndrome. New York: Springer; 2010. pp. 165-88. [DOI: 10.1007/978-1-4419-5641-5_10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
45 Yasui K, Uchida N, Akazawa Y, Nakamura S, Minami I, Amano Y, Yamazaki T. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis. 2008;14:396-400. [PMID: 17973303 DOI: 10.1002/ibd.20317] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
46 Hu H, Wang X, Liu S. Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review. Medicine (Baltimore) 2016;95:e4799. [PMID: 27603389 DOI: 10.1097/MD.0000000000004799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
47 Lee HJ, Cheon JH, Lee KJ, Jang HW, Jung KS, Jung ES, Lee JH, Jeon SM, Hong SP, Kim TI, Kim WH. Clinical Experience of Thalidomide in the Treatment of Korean Patients with Intestinal Behçet's Disease: Pilot Experience in a Single Center. Intest Res 2010;8:63. [DOI: 10.5217/ir.2010.8.1.63] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Cheon JH. Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists. J Rheum Dis 2021;28:4-16. [DOI: 10.4078/jrd.2021.28.1.4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs 2006;8:279-302. [PMID: 17037946 DOI: 10.2165/00148581-200608050-00002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
50 Clancy R, Ren Z, Turton J, Pang G, Wettstein A. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn’s disease correlates with enhanced TNF-alpha secretion. Dig Liver Dis. 2007;39:445-451. [PMID: 17317344 DOI: 10.1016/j.dld.2006.12.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
51 Mosli MH, Feagan BG, Sandborn WJ, Dʼhaens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis 2014;20:564-75. [PMID: 24412993 DOI: 10.1097/01.MIB.0000437986.00190.71] [Cited by in Crossref: 73] [Cited by in F6Publishing: 22] [Article Influence: 9.1] [Reference Citation Analysis]
52 Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 2003;79:127-32. [PMID: 12697909 DOI: 10.1136/pmj.79.929.127] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
53 Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis: EFFICACY AND ENDOSCOPIC PREDICTION OF CYTAPHERESIS THERAPY IN UC. Alimentary Pharmacology & Therapeutics 2006;24:147-52. [DOI: 10.1111/j.1365-2036.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
54 Lazzerini M, Martelossi S, Magazzù G, Pellegrino S, Lucanto MC, Barabino A, Calvi A, Arrigo S, Lionetti P, Lorusso M, Mangiantini F, Fontana M, Zuin G, Palla G, Maggiore G, Bramuzzo M, Pellegrin MC, Maschio M, Villanacci V, Manenti S, Decorti G, De Iudicibus S, Paparazzo R, Montico M, Ventura A. Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial. Inflamm Bowel Dis 2015;21:1739-49. [PMID: 26185909 DOI: 10.1097/MIB.0000000000000437] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
55 Johnson L, Jarvis J, Wilkins E, Hay P. Thalidomide Treatment for Refractory HIV‐Associated Colitis: A Case Series. CLIN INFECT DIS 2008;47:133-6. [DOI: 10.1086/588793] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
56 LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90. [PMID: 14512311 DOI: 10.1182/blood-2003-02-0361] [Cited by in Crossref: 206] [Cited by in F6Publishing: 195] [Article Influence: 10.8] [Reference Citation Analysis]
57 Metz T, Haque T, Chen H, Prakash S, Amre D, Das SK. Preparation and in vitro analysis of microcapsule thalidomide formulation for targeted suppression of TNF-alpha. Drug Deliv 2006;13:331-7. [PMID: 16877307 DOI: 10.1080/10717540500466097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
58 Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol 2006;22:30-43. [PMID: 16319674 DOI: 10.1097/01.mog.0000196151.74819.8e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
59 He Y, Mao R, Chen F, Xu PP, Chen BL, Wu Y, Qiu Y, Zhang SH, Feng R, Zeng ZR, Ben-Horin S, Chen MH. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. Therap Adv Gastroenterol 2017;10:397-406. [PMID: 28507598 DOI: 10.1177/1756283X17698910] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]